In the wake of the FDA Modernization Act and translational rates of cancer drugs into the clinic at just 20%, it is critical that oncology scientists invest in more translational and predictive models to de-risk the validation of novel targets, predict therapeutic response, and support biomarker discovery.

The Annual Tumor Models Boston Summit is the only industry-led meeting uniting 200+ industry experts from pharma, biotech, academic KOLs and preclinical CROs to delve into the latest case studies in leveraging PDX models, genetically engineered mouse models, advanced 3D in vitro models and more. An opportunity to join industry leaders developing teams in preclinical, translational, pharmacology, discovery, pharmacodynamics, toxicity and biology to optimize and implement more translatable oncology models.